Access the full text.
Sign up today, get DeepDyve free for 14 days.
LDL, low-density lipoprotein cholesterol
Supervision: Nissen
(2021)
and Drug Administration Briefing Document
G. Curfman (2020)
Do Omega-3 Fatty Acids Benefit Health?JAMA
M. Budoff, Deepak Bhatt, A. Kinninger, S. Lakshmanan, J. Muhlestein, V. Le, H. May, K. Shaikh, C. Shekar, Sion Roy, J. Tayek, J. Nelson (2020)
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trialEuropean Heart Journal, 41
Y. Saito, M. Yokoyama, H. Origasa, M. Matsuzaki, Y. Matsuzawa, Y. Ishikawa, S. Oikawa, J. Sasaki, H. Hishida, H. Itakura, T. Kita, A. Kitabatake, N. Nakaya, T. Sakata, K. Shimada, K. Shirato (2008)
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).Atherosclerosis, 200 1
J. Manson, N. Cook, I. Lee, W. Christen, S. Bassuk, S. Mora, Heike Gibson, C. Albert, D. Gordon, T. Copeland, Denise D’Agostino, G. Friedenberg, C. Ridge, V. Bubes, E. Giovannucci, W. Willett, J. Buring (2019)
Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and CancerThe New England Journal of Medicine, 380
HDL, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein
Stephen Nicholls, A. Lincoff, Michelle Garcia, Dianna Bash, C. Ballantyne, P. Barter, M. Davidson, J. Kastelein, W. Koenig, D. McGuire, D. Mozaffarian, P. Ridker, K. Ray, B. Katona, A. Himmelmann, Larrye Loss, M. Rensfeldt, Torbjörn Lundström, R. Agrawal, V. Menon, K. Wolski, S. Nissen (2020)
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.JAMA
L. Bowman, M. Mafham, K. Wallendszus, W. Stevens, G. Buck, J. Barton, K. Murphy, Theingi Aung, R. Haynes, J. Cox, A. Murawska, A. Young, M. Lay, Fang Chen, E. Sammons, E. Waters, A. Adler, J. Bodansky, A. Farmer, R. Mcpherson, A. Neil, D. Simpson, R. Peto, C. Baigent, R. Collins, S. Parish, J. Armitage (2018)
Effects of n‐3 Fatty Acid Supplements in Diabetes MellitusThe New England Journal of Medicine, 379
Abbreviations: DHA, docosahexaenoic acid
S. Nicholls, A. Lincoff, Dianna Bash, C. Ballantyne, P. Barter, M. Davidson, J. Kastelein, W. Koenig, Darren Mcguire, D. Mozaffarian, T. Pedersen, P. Ridker, K. Ray, B. Karlson, Torbjörn Lundström, K. Wolski, S. Nissen (2018)
Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trialClinical Cardiology, 41
Deepak Bhatt, P. Steg, Michael Miller, E. Brinton, T. Jacobson, S. Ketchum, R. Doyle, R. Juliano, L. Jiao, C. Granowitz, J. Tardif, C. Ballantyne (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaThe New England Journal of Medicine, 380
J. Bosch, H. Gerstein, G. Dagenais, R. Diaz, L. Dyal, Hyejung Jung, Aldo Maggiono, J. Probstfield, Ambady Ramachandran, M. Riddle, L. Rydén, S. Yusuf (2012)
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.The New England journal of medicine, 367 4
RBC, red blood cell
C. Degirolamo, L. Rudel (2010)
Dietary Monounsaturated Fatty Acids Appear Not to Provide CardioprotectionCurrent Atherosclerosis Reports, 12
Gissi-Prevenzione Investigators (1999)
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trialThe Lancet, 354
Key PointsQuestionIn statin-treated patients at high cardiovascular risk with elevated triglyceride levels and low levels of high-density lipoprotein cholesterol treated with ω-3 fatty acids, are achieved levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) associated with cardiovascular outcomes? FindingsIn a secondary analysis of a randomized clinical trial studying a carboxylic acid formulation of ω-3 fatty acids, plasma levels of EPA and DHA were measured 12 months after randomization in 10 382 patients. There was no association between achieved or change in level of either ω-3 fatty acid and major adverse cardiovascular events. MeaningThese findings do not support the concept that achieving higher EPA plasma levels through pharmacological means reduces adverse cardiovascular outcomes, nor were higher DHA levels associated with harm.
JAMA Cardiology – American Medical Association
Published: Aug 16, 2021
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.